Urinary iodine-to-creatinine ratio and outcomes after radioactive iodine ablation in thyroid cancer
Journal of the Endocrine Society · 08.07.2026 · 10 (8)
DOI: 10.1210/jendso/bvag125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 03.06.2026. Verfasst von Maria Vamvini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH, Joslin Diabetes Center Pilot & Feasibility.
Abstract (Originalsprache)
Context
Radioactive iodine ablation (RAIA) in differentiated thyroid cancer (DTC) requires elevated thyroid-stimulating hormone (TSH) levels, achieved through thyroid hormone withdrawal (THW) or recombinant human TSH (rhTSH). A low-iodine diet (LID) is recommended to enhance RAIA efficacy, but its impact on long-term outcomes remains uncertain.
Objective
To determine whether pre-ablation urinary iodine concentrations predict disease outcomes after RAIA.
Methods
This retrospective study evaluated DTC patients treated with post-surgical RAIA at BIDMC from 2007 to 2020. Of 463 patients reviewed, 304 met inclusion criteria (THW: 189; rhTSH: 115), all completing a 2-week LID; urinary iodine-to-creatinine ratio (UICR) was measured as iodine status marker. Disease recurrence at 12 months, defined by elevated thyroglobulin (Tg), abnormal neck ultrasound, or a positive whole-body scan, was the primary outcome, with associations between UICR and outcomes evaluated using univariable and multivariable logistic regression.
Results
Positive pre-treatment Tg (odds ratio [OR] 6.13, 95% CI 1.90-19.83; P = .002) and AJCC stage IV disease (OR 8.45, 95% CI 1.39-51.36; P = .02) were independently associated with recurrence. Older age was associated with lower recurrence risk only in unadjusted models. UICR showed no association with outcomes. Although mean UICR was higher in the rhTSH group (P < .0001), recurrence rates were similar between THW and rhTSH (P = .3).
Conclusion
Higher UICR in rhTSH-prepared patients did not translate into worse outcomes. Pre-treatment Tg and stage IV disease were the strongest predictors of recurrence, whereas iodine status was not. These findings suggest that strict iodine depletion at the level achieved here, reflected by UICR, may not determine RAIA efficacy in DTC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
- Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA.
- Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA 02138, USA.
- Diabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
- Division of Endocrinology, Diabetes, & Nutrition, Boston Medical Center-Brighton, Brighton, MA 02135, USA.
ORCID-Profile: Maria Vamvini, Ashna Grover, Josephine H Li, James V Hennessey
Förderung
- NIDDK NIH HHS
- NIH
- Joslin Diabetes Center Pilot & Feasibility
Zitieren
APA
Vamvini, M., Grover, A., Li, J. H., He, Z. H., & Hennessey, J. V. (2026). Urinary iodine-to-creatinine ratio and outcomes after radioactive iodine ablation in thyroid cancer. Journal of the Endocrine Society, 10(8). https://doi.org/10.1210/jendso/bvag125
Vancouver
Vamvini M, Grover A, Li JH, He ZH, Hennessey JV. Urinary iodine-to-creatinine ratio and outcomes after radioactive iodine ablation in thyroid cancer. Journal of the Endocrine Society. 2026;10(8). doi:10.1210/jendso/bvag125
BibTeX
@article{Vamvini2026,
author = {Vamvini, Maria and Grover, Ashna and Li, Josephine H and He, Zhiheng H and Hennessey, James V},
title = {Urinary iodine-to-creatinine ratio and outcomes after radioactive iodine ablation in thyroid cancer},
journal = {Journal of the Endocrine Society},
year = {2026},
volume = {10},
number = {8},
doi = {10.1210/jendso/bvag125}
}
EUVIMED